Global Liquid Biopsy Market Report to 2027: Featuring Abbott Laboratories, AccuraGen, BGI Genomics and Biocartis Among Others –

Global Liquid Biopsy Market Report to 2027: Featuring Abbott Laboratories, AccuraGen, BGI Genomics and Biocartis Among Others –

Global Liquid Biopsy Market Report to 2027: Featuring Abbott Laboratories, AccuraGen, BGI Genomics and Biocartis Among Others –

DUBLIN–(BUSINESS WIRE)–The “Liquid Biopsy Markets by Cancer, Usage, Biomarker, Place, & Product With Price and Volume Outlook. Including Executive and Consultant Guides and Customized Forecasting and Analysis 2023-2027” report has been added to’s offering.

The Screening, Diagnostic, Therapy Selection, Recurrence Monitoring and Screening Market Potential are all explored in this report. What is the impact of the COVID pandemic on the Liquid Biopsy market? The publisher looks at Price and Volume Outlooks by type of cancer.

This report provides detailed analysis. Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology has created the possibility of widespread screening for all types of cancers with a blood test.

Illumina is now working on the Circulating Cell-Free Genome Atlas (CCGA) to help identify cancer early. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has just moved out of the development phase and into the growth phase.

The impact on the health care industry is enormous. The report forecasts the market size looking out 5 years. In addition, the report looks at potential market sizes by country, by cancer and by the four types of usage: screening, diagnosis, therapy selection and recurrence monitoring.

Use independent research that makes you the expert. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don’t worry, your order is available as a credit if you wish to upgrade to more information. Get an extra player on your team as unlimited assistance and breakout data is included with your purchase.

The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate, Cervical, and Other Cancers as well as breakouts by Screening/Early Detection, Diagnostic, Therapy Monitoring and Recurrence Monitoring.

Companies Mentioned

  • Abbott Laboratories
  • AccuraGen Inc.
  • Acuamark Diagnostics
  • Admera Health, LLC
  • Agilent/Dako
  • Amoy Diagnostics Co., Ltd
  • Anchor Dx
  • ANGLE plc
  • Applied DNA Sciences
  • ARUP Laboratories
  • AVIVA Systems Biology
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc.
  • Biodesix Inc.
  • BioFluidica
  • bioMerieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Techne
  • Bioview
  • Bolidics
  • Boreal Genomics
  • Burning Rock
  • Cardiff Oncology
  • Caris Molecular Diagnostics
  • CellCarta
  • CellMax Life
  • Cepheid (Danaher)
  • Circulogene
  • Cizzle Biotech
  • Clinical Genomics
  • Cytolumina Technologies Corp
  • Datar Cancer Genetics Limited
  • Diagnologix LLC
  • Dxcover
  • Enzo Biochem
  • And Many More Companies!

Key Topics Covered:

1 Market Guides

2 Introduction and Market Definition

3 Market Overview

4 Market Trends

4.1 Factors Driving Growth

4.1.1 Non-Invasive Game Changer

4.1.2 Lower Cost

4.1.3 Greater Accuracy

4.1.4 Wide Range of Potential Uses

4.1.5 Aging Population

4.2 Factors Limiting Growth

4.2.1 Lower prices

4.2.2 Lack of Standards

4.2.3 Protocol Resistance

4.2.4 Initial Adoption Cost

4.2.5 Conclusion

4.3 Instrumentation and Automation

4.3.1 Instruments Key to Market Share

4.3.2 Bioinformatics Plays a Role

4.4 Diagnostic Technology Development

4.4.1 Next Generation Sequencing Fuels a Revolution

4.4.2 Impact of NGS on pricing

4.4.3 Pharmacogenomics Blurs Diagnosis and Treatment

4.4.4 CGES Testing, A Brave New World

4.4.5 Biochips/Giant magneto resistance based assay

5 Liquid Biopsy Recent Developments

6 Profiles of Key Players

7 The Global Market for Liquid Biopsy Diagnostics

8 Global Liquid Biopsy Diagnostic Markets – By Cancer

9 Global Liquid Biopsy Diagnostic Markets – by Usage

10 Global Liquid Biopsy Diagnostic Markets – by Place

11 Global Liquid Biopsy Diagnostic Markets – by Marker

12 Global Liquid Biopsy Diagnostic Markets – by Product

13 Appendices

For more information about this report visit


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900